{ "spec": "v1.1", "categories": [ { "id": "A", "name": "ํก์ˆ˜", "en": "Absorption", "icon": "๐Ÿซ—", "desc": "๋จน์€ ์•ฝ์ด ๋ชธ ์•ˆ์œผ๋กœ ๋“ค์–ด์˜ค๋Š”๊ฐ€", "planned": 8, "boards": [ "Solubility", "LogP", "Caco2" ], "desc_en": "Whether an orally dosed compound enters the body at all" }, { "id": "D", "name": "๋ถ„ํฌ", "en": "Distribution", "icon": "๐Ÿฉธ", "desc": "ํ˜ˆ์•ก ๋‹จ๋ฐฑ์งˆ์— ๋ถ™๋Š”๊ฐ€ ยท ๋‡Œ๊นŒ์ง€ ๊ฐ€๋Š”๊ฐ€", "planned": 5, "boards": [ "PPB", "Vdss" ], "desc_en": "Binding to plasma protein; passage across the blood-brain barrier" }, { "id": "M", "name": "๋Œ€์‚ฌ", "en": "Metabolism", "icon": "๐Ÿ”ฅ", "desc": "๊ฐ„์—์„œ ์–ผ๋งˆ๋‚˜ ๋นจ๋ฆฌ ์‚ฌ๋ผ์ง€๋Š”๊ฐ€ ยท ์–ด๋–ค ํšจ์†Œ๊ฐ€ ๊ฑด๋“œ๋ฆฌ๋Š”๊ฐ€", "planned": 7, "boards": [ "CYP3A4", "CYP2D6", "CYP2C9" ], "desc_en": "How quickly the liver clears it, and which enzymes act on it" }, { "id": "E", "name": "๋ฐฐ์„ค", "en": "Excretion", "icon": "๐Ÿ’ง", "desc": "๋ชธ ๋ฐ–์œผ๋กœ ์–ธ์ œ ๋‚˜๊ฐ€๋Š”๊ฐ€", "planned": 2, "boards": [ "HalfLife" ], "desc_en": "When the compound leaves the body" }, { "id": "T", "name": "๋…์„ฑ", "en": "Toxicity", "icon": "โ˜ ๏ธ", "desc": "์‹ฌ์žฅ ยท ๊ฐ„ ยท ๋ณ€์ด์›์„ฑ. ์‹ ์•ฝ์ด ๊ฐ€์žฅ ๋งŽ์ด ์ฃฝ๋Š” ์ž๋ฆฌ", "planned": 7, "boards": [ "hERG", "LD50" ], "desc_en": "Cardiac, hepatic and mutagenic liability โ€” where candidates most often fail" }, { "id": "P", "name": "ํšจ๋Šฅยท์—ญ๊ฐ€", "en": "Potency", "icon": "๐ŸŽฏ", "desc": "ํ‘œ์ ์— ์–ผ๋งˆ๋‚˜ ์„ธ๊ฒŒ ๋ถ™๋Š”๊ฐ€", "planned": 4, "boards": [ "AChE", "MAOB", "COX2", "Nav17" ], "desc_en": "How tightly a compound binds its intended target" }, { "id": "Z", "name": "์—ํ”ผ์ œ๋„คํ‹ฑ", "en": "Epigenetics", "icon": "๐Ÿ“–", "desc": "์œ ์ „์ž๋ฅผ ๋ฐ”๊พธ์ง€ ์•Š๊ณ  ์ฝ๋Š” ๋ฐฉ์‹์„ ๋ฐ”๊พผ๋‹ค", "desc_en": "Changing how genes are read without changing the genes", "planned": 5, "boards": [ "BRD4", "HDAC1" ] }, { "id": "N", "name": "ํ•ต์ˆ˜์šฉ์ฒด", "en": "Nuclear receptors", "icon": "๐Ÿงฟ", "desc": "ํ˜ธ๋ฅด๋ชฌ ์‹ ํ˜ธ๋ฅผ ๋ฐ›์•„ ์œ ์ „์ž๋ฅผ ์ผœ๊ณ  ๋ˆ๋‹ค โ€” ์œ ๋ฐฉ์•”ยท์ „๋ฆฝ์„ ์•” ํ‘œ์ ", "desc_en": "Hormone-driven transcription factors โ€” breast and prostate cancer targets", "planned": 5, "boards": [ "ERalpha", "AR" ] }, { "id": "E2", "name": "ํ”„๋กœํ…Œ์•„์ œ", "en": "Proteases", "icon": "โœ‚๏ธ", "desc": "๋‹จ๋ฐฑ์งˆ์„ ์ž๋ฅด๋Š” ํšจ์†Œ โ€” ์•Œ์ธ ํ•˜์ด๋จธยทํ•ญ์‘๊ณ ยทํ•ญ๋ฐ”์ด๋Ÿฌ์Šค๊ฐ€ ์—ฌ๊ธฐ ๊ฑธ๋ฆฐ๋‹ค", "desc_en": "Protein-cleaving enzymes behind Alzheimer, anticoagulant and antiviral programmes", "planned": 6, "boards": [ "BACE1", "Thrombin", "FactorXa" ] }, { "id": "K", "name": "ํ‚ค๋‚˜์•„์ œยท์„ ํƒ์„ฑ", "en": "Kinase & Selectivity", "icon": "๐Ÿ”‘", "desc": "ํ‚ค๋‚˜์•„์ œ ์ˆ˜๋ฐฑ ๊ฐœ ์ค‘ ์–ด๋””์— ๋ถ™๊ณ  ์–ด๋””๋Š” ํ”ผํ•˜๋Š”๊ฐ€", "planned": 13, "boards": [ "EGFR", "JAK2", "PI3Ka", "FLT3", "VEGFR2", "CDK2", "HER2", "ABL1", "BRAF", "KIT", "ALK", "Selectivity" ], "desc_en": "Which of several hundred kinases are engaged, and which are spared" }, { "id": "R", "name": "์ˆ˜์šฉ์ฒดยทGPCR", "en": "Receptors & GPCR", "icon": "๐Ÿ“ก", "desc": "์„ธํฌ ํ‘œ๋ฉด ์ˆ˜์šฉ์ฒด โ€” ์Šน์ธ์•ฝ ์„ธ ๊ฐœ ์ค‘ ํ•˜๋‚˜๊ฐ€ ์—ฌ๊ธฐ๋ฅผ ๋…ธ๋ฆฐ๋‹ค", "desc_en": "Cell-surface receptors โ€” the target class behind roughly a third of approved drugs", "planned": 8, "boards": [ "D2", "HT2A", "MuOpioid", "KappaOpioid", "A2A", "CB1" ] }, { "id": "S", "name": "๊ตฌ์กฐ๊ธฐ๋ฐ˜ ๊ฒฐํ•ฉ", "en": "Structure-based", "icon": "๐Ÿงฌ", "desc": "์–ด๋–ค ์ž์„ธ๋กœ ๋ถ™๋Š”๊ฐ€ ยท ๊ทธ ์ž์„ธ๊ฐ€ ๋ฌผ๋ฆฌ์ ์œผ๋กœ ๋ง์ด ๋˜๋Š”๊ฐ€", "planned": 4, "boards": [], "desc_en": "The binding pose, and whether that pose is physically admissible" }, { "id": "X", "name": "์„ธํฌยทํ‘œํ˜„ํ˜•", "en": "Cell & Phenomics", "icon": "๐Ÿ”ฌ", "desc": "์•ฝ์ด ์‹ค์ œ ์„ธํฌ์— ๋ฌด์Šจ ์ง“์„ ํ•˜๋Š”๊ฐ€", "planned": 5, "boards": [ "Phenotype" ], "desc_en": "What a compound actually does to a living cell" }, { "id": "I", "name": "ํ•ญ๊ฐ์—ผยท์ „์„ธํฌ", "en": "Anti-infective & whole-cell", "icon": "๐Ÿฆ ", "desc": "๊ท ๊ณผ ๊ธฐ์ƒ์ถฉ์ด ์‹ค์ œ๋กœ ์ฃฝ๋Š”๊ฐ€ โ€” ๋‹จ๋ฐฑ์งˆ์ด ์•„๋‹ˆ๋ผ ์ƒ๋ฌผ์„ ์ฝ๋Š”๋‹ค", "desc_en": "Whether the organism actually dies โ€” the readout is a living cell, not a protein", "planned": 6, "boards": [ "Malaria", "BSubtilis" ] }, { "id": "C", "name": "์ž„์ƒ ์ธ์‹ค๋ฆฌ์ฝ”", "en": "Clinical in-silico", "icon": "๐Ÿฅ", "desc": "์‚ฌ๋žŒ ๋ชธ์—์„œ์˜ ๋†๋„ ยท ์•ฝ๋ฌผ ์ถฉ๋Œ ยท ์šฉ๋Ÿ‰. ๊ฒจ๋ฃฐ ํ‘œ๊ฐ€ ์•„์ง ์—†๋Š” ์ž๋ฆฌ", "planned": 6, "boards": [ "Withdrawal" ], "desc_en": "Human exposure, drug-drug interaction and dose โ€” endpoints with no leaderboard yet" }, { "id": "G", "name": "์ƒ์„ฑยท๋ชจ๋‹ฌ๋ฆฌํ‹ฐ", "en": "Generation & Modality", "icon": "โš—๏ธ", "desc": "์ƒˆ๋กœ ๋งŒ๋“ค์–ด ๋‚ด๋Š” ์ชฝ ยท ์†Œ๋ถ„์ž๋ฅผ ๋„˜์–ด์„œ๋Š” ์ชฝ", "planned": 5, "boards": [], "desc_en": "Generating new matter, and modalities beyond small molecules" } ] }